According to epidemiological data, the prevention and control of chronic diseases in China remain a serious challenge. Recent epidemiological surveys indicate that the standardized prevalence rates of major chronic diseases, such as hypertension and diabetes, continue to rise, significantly impacting patients' health and quality of life. To thoroughly implement the strategic objectives outlined in the "Healthy China 2030" initiative, comprehensively fulfill the requirements of the "14th Five-Year Plan for National Health" regarding "strengthening comprehensive prevention and control of chronic diseases and injury prevention interventions," and effectively advance the implementation of the "Medium- to Long-Term Plan for the Prevention and Treatment of Chronic Diseases in China (2017–2025)," the Chengdu High-Tech Medical Association has scheduled a series of online training sessions on standardized diagnosis and treatment of chronic diseases - focusing on rational endocrine drug use from August to December 2025.

This series aims to systematically interpret the latest diagnostic and treatment guidelines and expert consensus on common chronic endocrine diseases, including diabetes, thyroid disorders, and osteoporosis. It will delve into key aspects and challenging issues of clinical rational drug use, share typical cases and practical experiences, and enhance healthcare professionals' understanding and application of endocrine drugs' characteristics, indications, adverse reactions, and interactions. By doing so, the sessions seek to standardize clinical diagnosis and treatment practices, ensure medical quality and patient safety, and ultimately provide more scientific, standardized, and effective long-term management solutions for chronic disease patients in the province.